A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden.

• PURPOSE: To assess resource utilization and costs associated with glaucoma management in France and Sweden. METHODS: A total of 267 patient records (121 in France, 146 in Sweden) with diagnoses of primary open-angle glaucoma (POAG) and ocular hypertension (OH), treated medically, were reviewed for a 2-year period (beginning during 1997-99) for relevant clinical and resource utilization data. Economic data were applied to estimate treatment costs. RESULTS: The annual cost of treating glaucoma was estimated at SEK5305 (531 euro )/patient in Sweden and 390 euro/patient in France. In both countries, medication costs comprised about half of the total costs. Surgical procedures and hospitalizations represented greater proportions of total cost in France (7.0% and 9.6%, respectively) than in Sweden (3.7% and 0.6%, respectively). CONCLUSION: Medication costs represent a high proportion of total treatment costs. These findings highlight the relative importance of medical therapy and of assessing the cost-effectiveness of medications in glaucoma.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Oftalmologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Ophthalmology (hsv//eng)

Nyckelord

Aged

Antihypertensive Agents

economics

Cost-Benefit Analysis

Drug Costs

Female

France

Glaucoma

Open-Angle

economics

therapy

Health Care Costs

Health Resources

economics

utilization

Humans

Intraocular Pressure

Male

Ocular Hypertension

economics

therapy

Ophthalmologic Surgical Procedures

economics

Retrospective Studies

Sweden

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)